Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 18c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($1.17), $0.18 worse than the analyst estimate of ($0.99). Revenue for the quarter came in at $110.4 million versus the consensus estimate of $99.38 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• UBS Upgrades Bajaj Finance Ltd. (BAF:IN) to Neutral
• AutoZone beats profit view but misses on revenue